Freestone Grove Partners’s CME Group CME Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$36M Buy
162,979
+106,826
+190% +$29.6M 0.23% 133
2026
Q1
$16.6M Sell
56,153
-63,870
-53% -$19M 0.12% 232
2025
Q4
$32.8M Buy
120,023
+72,593
+153% +$19.7M 0.24% 134
2025
Q3
$12.8M Buy
+47,430
New +$12.9M 0.1% 265
2025
Q1
Sell
-13,154
Closed -$3.05M 618
2024
Q4
$3.05M Buy
+13,154
New +$3.02M 0.04% 250

Other funds holding CME

Freestone Grove Partners's CME Position: Q2 2026 in Review

Freestone Grove Partners increased its CME Group (CME) stake by 190% in Q2 2026, buying an estimated $29.6M and bringing the position to 162,979 shares worth $36M. The position accounts for 0.23% of the portfolio, ranked #133.

Freestone Grove Partners first reported a position in CME in Q4 2024 and has held it in 5 quarters since. 1,703 funds tracked by Wall St. Rank hold CME as of Q2 2026.

  • Freestone Grove Partners held 162,979 shares of CME Group worth $36M as of Q2 2026.
  • Freestone Grove Partners bought 106,826 CME Group shares in Q2 2026, an estimated $29.6M.
  • CME Group made up 0.23% of Freestone Grove Partners's portfolio in Q2 2026, its #133 holding.
  • Freestone Grove Partners first reported a position in CME Group in Q4 2024 and has held it in 5 quarters since.
  • 1,703 funds tracked by Wall St. Rank held CME Group as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.